Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About HAE Interactive Breakdown Better Bets vs. HAE Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Haemonetics (HAE)

Market Price (10/23/2025): $51.34 | Market Cap: $2.5 Bil
Sector: Health Care | Industry: Health Care Supplies

Haemonetics (HAE)

Market Price (10/23/2025): $51.34
Market Cap: $2.5 Bil
Sector: Health Care
Industry: Health Care Supplies

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.6%, FCF Yield is 7.7%		 Weak multi-year price returns
2Y Excs Rtn is -99%, 3Y Excs Rtn is -116%		 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -4.4%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%		  
2 Low stock price volatility
Vol 12M is 45%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.6%, FCF Yield is 7.7%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 14%
2 Low stock price volatility
Vol 12M is 45%
3 Weak multi-year price returns
2Y Excs Rtn is -99%, 3Y Excs Rtn is -116%
4 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -4.4%

Market Valuation & Key Metrics

HAES&P 500
REVENUE GROWTH 
Rev LTM ($ Bil)1.3
Rev Chg Q-4.4%6.1%
Rev Chg LTM0.9%5.2%
Rev Chg 3Y Avg9.7%5.4%
PROFITABILITYFAIR
Op Inc LTM ($ Bil)0.2
CFO LTM ($ Bil)0.2
Net Inc LTM ($ Bil)0.2
Op Mgn LTM16.0%18.6%
CFO/Rev LTM16.8%20.4%
Net Inc Mgn12.1%12.7%
VALUATIONLOW
P/S1.83.3
P/CFO10.916.1
P/FCF13.121.2
P/E15.124.5
STABILITYGOOD
Debt/Equity0.500.21
Cash/Assets0.120.07

HAE Stock

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
HAE Return3%-55%48%9%-9%-34%-56%
Peers Return61%25%-27%5%-17%-17%5%
S&P 500 Return16%27%-19%24%23%14%106%

Monthly Win Rates [3]
HAE Win Rate50%42%67%58%42%22% 
Peers Win Rate58%62%47%57%40%44% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
HAE Max Drawdown-35%-58%-17%-8%-17%-39% 
Peers Max Drawdown-32%-4%-41%-18%-31%-37% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: MMSI, CNMD, STAA, IART, WST. See HAE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/22/2025 (YTD)

How Low Can It Go

Unique KeyEventHAES&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-68.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven218.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-39.0%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven63.9%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven294 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-29.9%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven42.7%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven63 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-25.3%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven33.9%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven707 days1480 days

Compare to MMSI, CNMD, STAA, IART, WST


In The Past

Haemonetics's stock fell -68.6% during the 2022 Inflation Shock from a high on 2/8/2021. A -68.6% loss requires a 218.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Haemonetics (HAE)

Better Bets than Haemonetics (HAE)

 HAEBetter Performance than HAE
MetricValueIndustry (Health Care Supplies)
Rev Chg LTM0.9%WST (2.9%), COO (6.4%), MMSI (8.2%), LNTH (5.7%), ICUI (3.0%)
Rev Chg 3Y Avg9.7%LNTH (34.3%), ICUI (10.7%), NEOG (23.2%)
Op Mgn LTM16.0%WST (21.0%), COO (18.3%), ALGN (16.1%), LNTH (28.9%)
CFO/Rev LTM16.8%WST (22.9%), COO (20.2%), ALGN (18.4%), LNTH (34.7%), BLFS (20.3%)
FCF/Rev LTM14.1%ALGN (15.9%), LNTH (31.1%), BLFS (15.0%)
Total Yield6.6%LNTH (6.9%)
 HAEBetter Performance than HAE
MetricValueAll Other Sectors
Rev Chg LTM0.9%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg9.7%NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM16.0%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM16.8%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM14.1%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield6.6%JPM (6.9%), XOM (9.7%), BAC (7.1%), BABA (38.0%), KO (6.8%)
null

Latest Trefis Analyses

Trade Ideas

Select past ideas related to HAE. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.0%3.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.3%6.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		16.1%16.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-0.9%-0.9%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.0%3.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.3%6.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		16.1%16.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-0.9%-0.9%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines221.6%139.6%
2VICRVicor49.6%77.5%
3CCOClear Channel Outdoor41.2%40.1%
4CELCCelcuity40.0%435.1%
5WGOWinnebago Industries34.9%-11.6%
6BALYBallys27.4%-2.4%
7TFINTriumph Financial27.3%-32.9%
8SIONSionna Therapeutics25.8% 
9LVWRLiveWire24.4%29.1%
10PMIPicard Medical24.4%20804.8%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BITFBitfarms-39.1%164.4%
2QBTSD-Wave Quantum-39.1%224.9%
3RGTIRigetti Computing-36.0%136.3%
4SMRNuScale Power-35.0%93.6%
5RCATRed Cat-31.9%-22.3%
6BKSYBlackSky Technology-31.3%101.3%
7OKLOOklo-30.0%465.8%
8QUBTQuantum Computing-30.0%-10.2%
9SESSES AI-29.9%13.2%
10ASPIASP Isotopes-29.4%96.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1366.7%342.6%
2QUREuniQure338.6%239.2%
3PRAXPraxis Precision Medicines279.5%139.6%
4LACLithium Americas117.9%125.3%
5CLPTClearPoint Neuro99.8%57.9%
6NVTSNavitas Semiconductor97.7%281.1%
7UAMYUnited States Antimony79.6%640.7%
8ORKAOruka Therapeutics71.3%37.4%
9GRALGRAIL69.8%346.8%
10TSHATaysha Gene Therapies69.2%185.5%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1SOCSable Offshore-51.7%-48.4%
2FLYFirefly Aerospace-37.4% 
3UPWheels Up Experience-37.0%-12.1%
4VGVenture Global-34.5% 
5PSIXPower Solutions International-33.0%160.7%
6ALABAstera Labs-32.7%16.9%
7FWRDForward Air-30.6%-41.0%
8QUBTQuantum Computing-30.5%-10.2%
9AEHRAehr Test Systems-29.6%42.4%
10TIPTTiptree-29.0%-15.1%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines221.6%139.6%
2VICRVicor49.6%77.5%
3CCOClear Channel Outdoor41.2%40.1%
4CELCCelcuity40.0%435.1%
5WGOWinnebago Industries34.9%-11.6%
6BALYBallys27.4%-2.4%
7TFINTriumph Financial27.3%-32.9%
8SIONSionna Therapeutics25.8% 
9LVWRLiveWire24.4%29.1%
10PMIPicard Medical24.4%20804.8%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BITFBitfarms-39.1%164.4%
2QBTSD-Wave Quantum-39.1%224.9%
3RGTIRigetti Computing-36.0%136.3%
4SMRNuScale Power-35.0%93.6%
5RCATRed Cat-31.9%-22.3%
6BKSYBlackSky Technology-31.3%101.3%
7OKLOOklo-30.0%465.8%
8QUBTQuantum Computing-30.0%-10.2%
9SESSES AI-29.9%13.2%
10ASPIASP Isotopes-29.4%96.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Haemonetics

Financials

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
Mkt Price51.3484.5248.7724.9015.46277.0050.06
Mkt Cap2.55.01.51.21.220.02.0
Rev LTM1,3461,3881,3162241,6242,9601,367
Op Inc LTM215162181-829622172
FCF LTM189178165-44-25344171
FCF 3Y Avg128125104-1078366115
CFO LTM227225179-29102677202
CFO 3Y Avg2041701228159712165

Growth & Margins

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
Rev Chg LTM0.9%8.2%4.3%-32.6%6.2%2.9%3.6%
Rev Chg 3Y Avg9.7%8.0%8.9%-2.3%1.4%0.4%4.7%
Rev Chg Q-4.4%9.8%2.9%-55.2%3.7%9.2%3.3%
QoQ Delta Rev Chg LTM-1.1%2.3%0.7%-19.6%0.9%2.2%0.8%
Op Mgn LTM16.0%11.7%13.8%-36.4%0.6%21.0%12.7%
Op Mgn 3Y Avg14.2%10.5%10.2%-6.7%6.8%22.2%10.4%
QoQ Delta Op Mgn LTM1.2%0.2%-1.6%-20.2%-1.2%0.5%-0.5%
CFO/Rev LTM16.8%16.2%13.6%-12.7%6.3%22.9%14.9%
CFO/Rev 3Y Avg15.8%13.1%9.6%1.2%10.2%24.6%11.6%
FCF/Rev LTM14.1%12.8%12.5%-19.5%-1.6%11.6%12.1%
FCF/Rev 3Y Avg9.8%9.5%8.1%-5.2%5.1%12.6%8.8%

Valuation

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
Mkt Cap2.55.01.51.21.220.02.0
P/S1.83.61.15.50.76.82.7
P/EBIT10.527.28.3-15.136.133.518.8
P/E15.140.712.7-12.9-40.841.013.9
P/CFO10.922.18.4-43.211.529.611.2
Total Yield6.6%2.5%9.5%-7.7%-2.4%2.6%2.5%
Dividend Yield0.0%0.0%1.6%0.0%0.0%0.2%0.0%
FCF Yield 3Y Avg3.3%2.4%5.7%-1.6%2.0%1.7%2.2%
D/E0.50.20.60.01.70.00.3
Net D/E0.40.10.6-0.11.5-0.00.2

Returns

HAEMMSICNMDSTAAIARTWSTMedian
NameHaemonet.Merit Me.Conmed Staar Su.Integra .West Pha. 
1M Rtn0.3%1.1%-2.5%-7.3%7.3%9.8%0.7%
3M Rtn-31.1%-0.6%-2.5%29.1%20.8%21.9%10.1%
6M Rtn-14.9%-9.9%-1.2%43.1%-4.9%27.2%-3.0%
12M Rtn-31.1%-11.6%-21.6%-18.1%-19.4%-3.0%-18.8%
3Y Rtn-35.8%45.9%-34.8%-64.5%-63.9%19.8%-35.3%
1M Excs Rtn0.7%0.3%-0.2%-6.9%10.0%9.8%0.5%
3M Excs Rtn-36.1%-4.9%-6.5%25.9%16.4%-6.0%-5.5%
6M Excs Rtn-39.5%-34.5%-25.8%18.5%-29.5%2.6%-27.7%
12M Excs Rtn-46.8%-26.6%-39.7%-34.1%-36.4%-19.5%-35.2%
3Y Excs Rtn-116.1%-34.6%-118.1%-147.5%-147.0%-72.9%-117.1%

Comparison Analyses

Title
0How Does Haemonetics Stock Stack Up Against Its Peers?
1Haemonetics vs. Merit Medical Systems: With Return Forecast Of 41%, Haemonetics Is A Better Bet
2Haemonetics vs. Integra LifeSciences: With Return Forecast Of 56%, Integra LifeSciences Is A Better Bet
3With 18% Gains On The Table, CNMD May Outshine HAE
4Haemonetics vs. Alnylam Pharmaceuticals: With Return Forecast Of 85%, Alnylam Pharmaceuticals Is A Better Bet
5Haemonetics vs. ABIOMED: With Return Forecast Of 68%, ABIOMED Is A Better Bet
6Haemonetics vs. Paycom Software: With Return Forecast Of 92%, Paycom Software Is A Better Bet
7Haemonetics vs. Kulicke and Soffa Industries: Similar Market Cap, Similar Bets
8Haemonetics vs. Installed Building Products: Similar Market Cap, But Installed Building Products Is A Better Bet
9Haemonetics vs Allete: Similar Market Cap; Which Stock Is A Better Bet?

Financials

$ Mil | FY: 3/292026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q2
Period End6/28/20253/29/202512/28/20249/28/20246/29/20243/30/202412/30/20239/30/20237/1/20234/1/202312/31/202210/1/2022
Filing Date8/7/20255/21/20252/6/202511/7/20248/8/20245/20/20242/8/202411/2/20238/8/20235/22/20232/7/202311/8/2022
Key Financials Quarterly            
Total Revenue321331349346336343336318311304305297
Ebitda8310088816958705877596770
Operating Income545159524038463554354347
Net Income345837343820312541293333
EPS0.711.180.750.660.750.400.620.490.810.580.650.65
Key Financials TTM            
Total Revenue TTM1,3461,3611,3741,3611,3341,3091,2701,2391,2191,1691,1291,084
Ebitda TTM351337295277254262264261273249234227
Operating Income TTM215201189176159173170167179156140132
Net Income TTM1631681301241151181271281371159686
Growth Rates Quarterly            
Total Revenue Growth-4.4%-3.7%3.7%8.6%8.0%12.8%10.1%7.0%19.1%14.9%17.5%24.0%
EBITDA Growth19.9%72.9%26.7%38.8%-10.2%-2.6%4.0%-16.9%44.1%34.3%11.4%46.0%
Operating Income Growth35.5%32.2%28.4%46.4%-25.9%10.0%6.2%-24.5%74.4%81.6%21.4%90.7%
Net Income Growth-11.3%184.7%20.0%35.8%-6.5%-30.7%-5.2%-25.0%106.5%201.6%41.8%123.5%
Margins Quarterly            
EBITDA Margin25.7%30.1%25.3%23.4%20.5%16.8%20.7%18.3%24.6%19.4%21.9%23.6%
Operating Income Margin16.8%15.3%16.9%15.0%11.8%11.2%13.7%11.1%17.2%11.5%14.2%15.7%
Net Income Margin10.6%17.5%10.8%9.8%11.4%5.9%9.3%7.8%13.2%9.7%10.8%11.2%
Cash & Debt            
Total Cash293307321299344179194351286284224241
Total Debt1,2251,2251,2251,2251,224808871762765766767818
Net Debt / (Cash)932918904926879629677411479481543577
Cash Flows Quarterly            
FCF from Operations171174449-2764-19919806487
Cash Flows TTM            
FCF from Operations TTM22718212985135182197262250273261260
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0150-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC11.1%12.0%12.5%10.9%9.3%10.9%10.2%10.8%16.1%12.0%12.3%13.7%
Return on Invested Capital (ROIC) TTM            
ROIC TTM11.5%11.5%10.5%9.5%8.9%10.9%10.4%13.5%13.7%12.1%9.9%9.1%

Price Behavior

HAE Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta2.141.251.320.850.770.73
Up Beta1.602.101.400.940.860.69
Down Beta1.19-4.56-2.380.210.270.55
Up Capture39%25%52%85%58%34%
Bmk +ve Days13233574144420
Stock +ve Days7152659117381
Down Capture485%496%424%163%122%101%
Bmk -ve Days8192952107330
Stock -ve Days14263664131366

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity3,133,216
Short Interest: % Change Since 9152025-7.6%
Average Daily Volume1,265,153
Days-to-Cover Short Interest2.48
Basic Shares Quantity48,111,000
Short % of Basic Shares6.5%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/7/2025-26.6%-28.9%-28.2%
5/8/20255.9%6.8%9.7%
2/6/2025-11.6%-13.9%-3.6%
11/7/202410.7%17.4%3.9%
8/8/2024-10.8%-14.6%-14.6%
5/9/2024-0.7%3.5%-8.2%
2/8/20241.3%-7.6%3.2%
11/2/2023-1.1%-0.3%-2.5%
...
SUMMARY STATS   
# Positive131213
# Negative101110
Median Positive7.3%7.3%6.3%
Median Negative-8.8%-7.0%-7.4%
Max Positive16.2%23.8%33.1%
Max Negative-26.6%-28.9%-28.2%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/28/2025
3312025521202510-K 3/29/2025
12312024206202510-Q 12/28/2024
93020241107202410-Q 9/28/2024
6302024808202410-Q 6/29/2024
3312024520202410-K 3/30/2024
12312023208202410-Q 12/30/2023
93020231102202310-Q 9/30/2023
6302023808202310-Q 7/1/2023
3312023522202310-K 4/1/2023
12312022207202310-Q 12/31/2022
93020221108202210-Q 10/1/2022
6302022810202210-Q 7/2/2022
3312022525202210-K 4/2/2022
12312021208202210-Q 1/1/2022
93020211109202110-Q 10/2/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.